RMRoman Manetsch

Roman Manetsch

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Roman Manetsch has a total of 223 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Intact protein mass spectrometry imaging at isotopic resolution enables assessment of covalent drug candidates

    by Rutali R. Brahme, Md Amin Hossain, Brandon C. Miller, Gerard Baquer, Michael Scott Regan, Jared R. Auclair, Roman Manetsch, Nathalie Y. R. Agar, Jeffrey N. Agar

  • Open Access

    Cyclic Thiosulfinates: Synthesis and Applications in Chemical Biology and Materials Science

    by Benjamin Liebson, Jeffrey N. Agar, Roman Manetsch, Prakash T. Parvatkar

    Cyclic thiosulfinates (CTs) constitute a distinct class of organosulfur compounds characterized by a polarized ─S(═O)─S─ motif and inherent ring strain, which together dictate their unique reactivity toward thiols. Recent advances in synthetic methodologies, particularly the controlled oxidation of cyclic disulfides, have enabled access to stable CTs with tunable ring sizes and substitution patterns. Mechanistic studies reveal that ring‐induced hyperconjugation and conformational constraints enhance nucleophilic substitution, allowing for selective cross‐linking of proximal thiols while minimizing the modification of isolated thiols. These properties have positioned CTs as valuable tools in chemical biology for selective thiol targeting and protein cross‐linking in complex biological environments. Concurrently, CTs are gaining prominence as dynamic covalent cross‐linkers in materials science. This review highlights recent progress in the synthesis, reactivity, and applications of CTs across chemical biology and materials science.

  • Unlocking the potential of ommatins as sustainable photosensitizers for photodynamic therapy

    by Arif Hussain, Anthony A. Ruberto, Harsh Bhatia, Steven P. Maher, Yifan Quan, Lili Huang, André Barateiro, Gia-Bao Nguyen, David Budil, Hannah Sayre, et al.

  • Open Access

    Legacy 4(1 H )-quinolone scaffolds activity against acute and chronic Toxoplasma gondii infection

    by Melissa A. Sleda, Khaly Diagne, Victoria M. Clifton, Baihetiya Baierna, Roman Manetsch, Silvia N J Moreno

    Toxoplasma gondii is a protozoan parasite capable of infecting most warm-blooded animals, including humans, and can cause severe disease in immunocompromised individuals and the developing fetus. Current treatments for toxoplasmosis are effective only against the acute stage of infection and have limited or no activity against the latent bradyzoite stage found within tissue cysts. The mitochondrion of T. gondii is a validated drug target, and the clinically used drug atovaquone acts by inhibiting the mitochondrial electron transport chain (ETC) at the coenzyme Q:cytochrome c oxidoreductase ( bc 1 complex). In this study, we evaluate two legacy 4(1 H )-quinolones: ICI 56,780 and WR 243246, previously shown to inhibit the Plasmodium falciparum bc 1 complex, for their efficacy against T. gondii . Both compounds inhibit tachyzoite growth with low-nanomolar EC₅₀ values and disrupt parasite mitochondrial function by blocking cytochrome c reduction and collapsing the mitochondrial membrane potential. Notably, ICI 56,780 protects mice from lethal infection with type I RH tachyzoites. Importantly, ICI 56,780 also exhibits potent activity against chronic-stage parasites, reducing cyst size and bradyzoite viability in vitro and showing low-nanomolar EC₅₀ values against in vivo -derived bradyzoites. In mice chronically infected with T. gondii , treatment with ICI 56,780 significantly decreases brain cyst burden. Although these 4(1 H )-quinolones display some pharmacokinetic limitations, our findings highlight their potential as promising chemotypes active against both acute and chronic stages of T. gondii and provide a framework for future medicinal chemistry efforts to improve drug-like properties while preserving or enhancing anti-bradyzoite activity.

  • Open Access

    Discovery and optimization of a novel carboxamide scaffold with selective antimalarial activity

    by Alicia Wagner, Roger Trombley, Maris Podgurski, Anthony A. Ruberto, Meng Cui, Caitlin A. Cooper, William E. Long, Gia-Bao Nguyen, Adriana A. Marin, Sarah Lee Mai, et al.


  • Open Access

    Mass spectrometry methods and mathematical PK/PD model for decision tree-guided covalent drug development

    by Amin Hossain, Rutali R. Brahme, Brandon C. Miller, Jakal Amin, Marcela de Barros, Jaime L. Schneider, Jared R. Auclair, Carla Mattos, Qingping Wang, Nathalie Y. R. Agar, et al.

    Covalent drug discovery efforts are growing rapidly but have major unaddressed limitations. These include high false positive rates during hit-to-lead identification; the inherent uncoupling of covalent drug concentration and effect [i.e., uncoupling of pharmacokinetics (PK) and pharmacodynamics (PD)]; and a lack of bioanalytical and modeling methods for determining PK and PD parameters. We present a covalent drug discovery workflow that addresses these limitations. Our bioanalytical methods are based upon a mass spectrometry (MS) assay that can measure the percentage of drug-target protein conjugation (% target engagement) in biological matrices. Further we develop an intact protein PK/PD model (iPK/PD) that outputs PK parameters (absorption and distribution) as well as PD parameters (mechanism of action, protein metabolic half-lives, dose, regimen, effect) based on time-dependent target engagement data. Notably, the iPK/PD model is applicable to any measurement (e.g., bottom-up MS and other drug binding studies) that yields % of target engaged. A Decision Tree is presented to guide researchers through the covalent drug development process. Our bioanalytical methods and the Decision Tree are applied to two approved drugs (ibrutinib and sotorasib); the most common plasma off-target, human serum albumin; three protein targets (KRAS, BTK, SOD1), and to a promising SOD1-targeting ALS drug candidates.


  • Open Access

    Development of CGS-15943 Adjunctives for the Disruption of Plasmid Maintenance in Multidrug Resistant E. coli

    by Mintesinot Kassu, Katelyn E. Zulauf, Jessica N. Ross, James E. Kirby, Roman Manetsch

    Carbapenemase producing Enterobacterales (CPEs) represent a group of multidrug resistant pathogens for which few, if any, therapeutics options remain available. CPEs generally harbor plasmids that encode resistance to last resort carbapenems and many other antibiotics. We previously performed a high throughput screen to identify compounds that can disrupt the maintenance and replication of resistance conferring plasmids through use of a synthetic screening plasmid introduced into Escherichia coli K-12 tolC cells. Despite being identified as a potent and selective antiplasmid agent through this screening effort, CGS-15943 was inactive in wild-type E. coli, suggesting that it is susceptible to TolC-mediated efflux. Herein, a series of analogues were developed to confirm the activity of the triazoloquinazoline chemotype and overcome efflux observed in wild-type E. coli K-12. Two analogues demonstrated superior antiplasmid activity to CGS-15943 in E. coli tolC mutants, while one compound displayed moderate activity in wild-type E. coli at low concentrations.


  • Open Access

    Discovery and Optimization of a Novel Carboxamide Scaffold with Selective Antimalarial Activity

    by Alicia Wagner, Roger Trombley, Maris Podgurski, Anthony A. Ruberto, Meng Cui, Caitlin A. Cooper, William E. Long, Gia-Bao Nguyen, Adriana A. Marin, Sarah Lee Mai, et al.

    Artemisinin combination therapies (ACTs) are critical components of malaria control worldwide. Alarmingly, ACTs have begun to fail, owing to the rise in artemisinin resistance. Thus, there is an urgent need for an expanded set of novel antimalarials to generate new combination therapies. Herein, through a virtual high-throughput screen (vHTS), cheminformatics-driven down-selection, and structure-activity relationship (SAR) studies, we have identified a 1,2,4-triazole-containing carboxamide scaffold; while the most promising triazole displayed 519 nM potency against the asexual blood stages of the parasite, this activity was unable to be surpassed. Scaffold hopping efforts then revealed three alternative cores with up to a 2.5-fold increase in potency from the aforementioned front-runner triazole. The lead compound of this class, a deuterated picolinamide, displays moderate aqueous solubility (13.4 µM) and metabolic stability (CLintapp HLM 17.3 µL/min/mg) in vitro, as well as moderate oral bioavailability (% F 16.2) in in vivo pharmacokinetic studies. Front-runners representing three cores were confirmed potent against a panel of three clinical isolates harboring different resistance profiles, suggesting a novel mechanism of action, and the lead compound displayed a slow-to-moderate rate of killing (average PRR 2.4) in a parasite reduction ratio assay, making the series appealing for further development.

  • Open Access

    Efficient Biomimetic Total Synthesis, Characterization, and Antioxidant Activity of Ommatins

    by Lili Huang, Taehwan Kim, Olivia J. Armendarez, Leila F. Deravi, Prakash T. Parvatkar, Roman Manetsch

    Ommatins, natural colorants found in cephalopods and arthropods, are biosynthesized from tryptophan with uncyclized xanthommatin (Uc-Xa) as the key biosynthetic precursor. These pigments change color under oxidative or reductive conditions. Xanthommatin (Xa) and dihydro-xanthommatin (H2-Xa), as well as decarboxylated xanthommatin (Dc-Xa) and decarboxylated-dihydro-xanthommatin (Dc-H2-Xa), are some of the most common and well-studied ommatins. Herein, we describe the biomimetic total synthesis of Xa/H2-Xa on a gram scale by using the Mannich reaction and oxidative dimerization as the key steps. The 7-step linear synthetic sequence achieved an overall yield of 27%. Dc-Xa/Dc-H2-Xa and protected Uc-Xa/Uc-H2-Xa were also synthesized from the common intermediate-protected 3-hydroxykynurenine (3-OHK). The synthesized ommatins underwent thorough characterization using various spectroscopic techniques, including NMR, UV-vis, FTIR, HRMS, and LC-MS. Their optoelectronic properties were studied using spectrophotometry and electrochemical analysis. Furthermore, the antioxidant activity of the synthesized ommatins was evaluated using an oxygen radical antioxidant capacity activity assay. The results indicated that Dc-Xa exhibited the highest antioxidant activity, followed by Xa, while Uc-Xa showed the lowest activity.


  • Open Access

    Chemoselective seleno-click amidation in kinetic target-guided synthesis

    by Lili Huang, Prakash T. Parvatkar, Alicia Wagner, Sameer S. Kulkarni, Roman Manetsch

    Capitalizing on our previous kinetic target-guided synthesis (KTGS) involving the sulfo-click reaction to form N-acylsulfonamide-linked inhibitors in the presence of the protein–protein interaction target Mcl-1, we herein report a seleno-click approach for amide-linked inhibitors of Mcl-1. The seleno-click reaction leverages the enhanced reactivity of selenocarboxylates, enabling the templated amidation with electron-rich azides, thereby expanding the scope of KTGS. The potential of this approach is demonstrated by generating N-benzyl-5-(4-isopropylthiophenol)-2-hydroxyl nicotinamide, a known Mcl-1 inhibitor featuring an amide, via KTGS at 37 °C against Mcl-1. Notably, the seleno-click strategy was also effective at 4 °C, offering a variant for thermally sensitive biological targets.